Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphangioleiomyomatosis × Hydroxychloroquine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 10 Breast Neoplasms 7 Prostatic Neoplasms 6 Colorectal Neoplasms 6 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Multiple Myeloma 3 Melanoma 3 Gastrointestinal Neoplasms 3 COVID-19 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumor 2 Recurrence 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Leukemia 2 Glioblastoma 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Adenocarcinoma of Lung 2 Urologic Diseases 1 Untreated Resectable Pancreatic Adenocarcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Respiratory Distress Syndrome 1 Resectable Localized Prostate Cancer 1

Interventions

Sirolimus 9 Everolimus 3 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 carbon-11 acetate 1 Valproic Acid 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01687179 2018-10-11

SAIL

Brigham and Women's Hospital

Phase 1 Completed

14 enrolled 14 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡